Cargando…
Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform
For the efficacy of COVID-19 vaccines, emergence of variants accumulating immune-escape mutations remains a major concern. We analyzed the anti-variant (n = 10) neutralization activity of sera from COVID-19 patients infected with Wuhan (B.1), Kappa, and Delta variants and COVISHIELD vaccine recipien...
Autores principales: | Patil, Rajashree, Palkar, Sonali, Mishra, Akhileshchandra, Patil, Rahul, Arankalle, Vidya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277512/ https://www.ncbi.nlm.nih.gov/pubmed/37342350 http://dx.doi.org/10.3389/fimmu.2023.1181991 |
Ejemplares similares
-
Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
por: Melloul, Marouane, et al.
Publicado: (2021) -
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion
por: Ren, Wenlin, et al.
Publicado: (2022) -
Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021) -
Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022) -
Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
por: Epaulard, Olivier, et al.
Publicado: (2022)